#Ireland #Dublin #TERLIVAZ #Keenova #HRS-AKI

Keenova Therapeutics Showcases New Data on TERLIVAZ® at Kidney Week 2026

Keenova Therapeutics plc recently announced an exciting update regarding its product TERLIVAZ® (terlipressin) during the American Society of Nephrology's Kidney Week 2026, which took place from October 21 to 25. The company presented two significant analyses focused on hepatorenal syndrome-acute kidney injury (HRS-AKI) that promise to enhance understanding and treatment of this serious condition.

Importance of the Presentations

The data, presented by experts in the field, underscores the crucial role of TERLIVAZ in managing HRS-AKI — a life-threatening condition characterized by rapid declines in kidney function due to underlying liver disease. Dr. Marek Honczarenko, Keenova's Executive Vice President and Chief Scientific Officer, emphasized the significance of these presentations in supporting the therapeutic value of TERLIVAZ. He stated, "These presentations add to the growing body of evidence supporting the use of TERLIVAZ in HRS-AKI. By examining treatment outcomes in both clinical trial and real-world settings, these analyses provide valuable insights that can help inform treatment decisions and patient care."

Key Presentation Details

During the conference, two key presentations were highlighted:

1. Retrospective Cohort Study on Terlipressin
This study evaluated the real-world utilization and outcomes of terlipressin among U.S. adults hospitalized with hepatorenal syndrome-acute kidney injury.
Authors: A. Sidney Barritt IV, MD, MSCR; Kavish R. Patidar, DO; Robert J. Wong, MD, MS; among others.
Poster Session Date: October 22
Poster Board: #TH-PO0769

2. Exploratory Subgroup Analysis from the CONFIRM Trial
This analysis looked into the effects of terlipressin and renal replacement therapy in patients with HRS-AKI who were ineligible for liver transplantation.
Authors: Kevin Regner, MD, MS; Nancy Reau, MD; Kavish Patidar, MD; and others.
Oral Abstract Session Date: October 24
Abstract Publication: #SA-OR014

Understanding Hepatorenal Syndrome-Acute Kidney Injury

Hepatorenal syndrome-acute kidney injury is a serious condition commonly associated with advanced liver disease, leading to high morbidity and mortality rates. This condition is recognized as an acute medical emergency that necessitates immediate hospitalization to effectively manage rapid kidney decline. Recent studies indicate that the annual incidence of hospitalization for HRS has dramatically increased in the United States, showcasing the growing need for effective therapeutic options like TERLIVAZ.

About TERLIVAZ

As the first FDA-approved therapy for enhancing kidney function in adults with HRS-AKI, TERLIVAZ stands out in its ability to address a critical unmet medical need. However, it's crucial to note the limitations and safety warnings associated with its use. For instance, patients with a serum creatinine level greater than 5 mg/dL are unlikely to benefit from TERLIVAZ.

Safety Considerations

Patients must be carefully monitored for signs of respiratory failure, which can be serious or even fatal. Thus, prior to treatment initiation, thorough evaluations must be conducted. The safety profile also includes contraindications for patients experiencing hypoxia as well as those with ongoing ischemic conditions. Following administration, continuous monitoring of patients' respiratory status is essential, ensuring the treatment’s benefits do not outweigh its risks.

Future Directions for Keenova

Keenova Therapeutics continues to position itself at the forefront of innovation in treating rare or challenging medical conditions. The company has a diversified portfolio spanning several specialty therapeutic areas. Keenova is headquartered in Dublin, Ireland, but boasts a robust manufacturing presence in the United States, which further solidifies its capability to address the needs of patients across multiple demographics.

The presentations at Kidney Week highlight a significant step forward in understanding treatments for HRS-AKI and the ongoing commitment of Keenova Therapeutics to remain a leader in the therapeutics landscape. As the landscape continues to evolve, Keenova’s research and insights into terlipressin will undoubtedly pave the way for improved patient outcomes in the future.